Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.

Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA.

PLoS One. 2009 Jul 16;4(7):e6251. doi: 10.1371/journal.pone.0006251.

2.

[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].

Dank M.

Orv Hetil. 2001 Nov 18;142(46):2563-8. Review. Hungarian.

PMID:
11770175
3.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.

Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.

PMID:
16683005
4.

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Yeon CH, Pegram MD.

Invest New Drugs. 2005 Oct;23(5):391-409. Review.

PMID:
16133791
5.

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.

Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. Review.

PMID:
10482195
7.

Trastuzumab and breast cancer: developments and current status.

Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, Maehara Y.

Int J Clin Oncol. 2006 Jun;11(3):199-208. Review.

PMID:
16850126
9.

Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.

Conte P, Guarneri V, Bengala C.

Clin Breast Cancer. 2007 Dec;7(11):841-9. doi: 10.3816/CBC.2007.n.048. Review.

PMID:
18269773
10.

Her2-positive breast cancer: herceptin and beyond.

Dean-Colomb W, Esteva FJ.

Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18. Review.

PMID:
19022660
11.
12.

Mechanism of action of anti-HER2 monoclonal antibodies.

Baselga J, Albanell J.

Ann Oncol. 2001;12 Suppl 1:S35-41. Review.

PMID:
11521720
13.

Targeting HER2: recent developments and future directions for breast cancer patients.

Wang SC, Zhang L, Hortobagyi GN, Hung MC.

Semin Oncol. 2001 Dec;28(6 Suppl 18):21-9. Review.

PMID:
11774202
14.

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.

Lane HA, Motoyama AB, Beuvink I, Hynes NE.

Ann Oncol. 2001;12 Suppl 1:S21-2. Review.

PMID:
11521716
15.

[Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].

Beuzeboc P, Scholl S, Garau XS, Vincent-Salomon A, Cremoux PD, Couturier J, PalangiƩ T, Pouillart P.

Bull Cancer. 1999 Jun;86(6):544-9. Review. French.

PMID:
10417428
16.

Antibodies as molecular target-based therapy: trastuzumab.

Tokuda Y.

Int J Clin Oncol. 2003 Aug;8(4):224-9. Review.

PMID:
12955577
17.

HER2 as a target for breast cancer therapy.

Tagliabue E, Balsari A, Campiglio M, Pupa SM.

Expert Opin Biol Ther. 2010 May;10(5):711-24. doi: 10.1517/14712591003689972. Review.

PMID:
20214497
18.

HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches.

Colombo M, Corsi F, Foschi D, Mazzantini E, Mazzucchelli S, Morasso C, Occhipinti E, Polito L, Prosperi D, Ronchi S, Verderio P.

Pharmacol Res. 2010 Aug;62(2):150-65. doi: 10.1016/j.phrs.2010.01.013. Epub 2010 Feb 1. Review.

PMID:
20117211
19.

The importance of autophagy regulation in breast cancer development and treatment.

Zarzynska JM.

Biomed Res Int. 2014;2014:710345. doi: 10.1155/2014/710345. Epub 2014 Sep 17. Review.

20.

Autophagy and cancer.

Choi KS.

Exp Mol Med. 2012 Feb 29;44(2):109-20. doi: 10.3858/emm.2012.44.2.033. Review.

Items per page

Supplemental Content

Write to the Help Desk